Official Title
Detection of Tumor DNA in Blood Samples From Patients With Late Stage Cancer and "Healthy Controls"
Brief Title
Detection of Tumor DNA in Blood Samples From Cancer Patients
Protocol ID
NCT02288754
Lead Sponsor
Lexent Bio, Inc.
Brief Summary
The aim of this study is to employ genomic detection methodologies to measure the
relative amount of tumor nucleic acids in the blood of a cancer patient with diagnosed
metastatic disease that is either commencing, currently undergoing or completed cytotoxic
chemotherapy treatment. More generally, this approach will allow us to develop a
quantitative measure of therapy efficacy via the counting of the relative changes in
tumor molecules over the course of treatment.
Enrollment Count
500 participants
Eligibility Criteria
Inclusion Criteria:
- Age 18 years or older
- Have metastatic disease with from a solid tumor (e.g. breast, lung, colon, pancreas,
ovary, prostate...) or stage II or III solid tumors undergoing curative surgery or
neoadjuvant therapy followed by surgery
- Starting treatment or a new line of treatment
- Able to understand and grant informed consent
- Able to have their blood drawn
Exclusion Criteria:
- Unable to grant informed consent or comply with all study procedures.
- Has a hematological malignancy, i.e. myeloma, lymphoma, MDS, leukemia
Filters
Cancer
Tumors
UNKNOWN
ADULT
OLDER_ADULT